2020 Annual Conference   |   April 1-3, 2020   |   Salt Lake City, Utah, USA

Sponsorships are now available, learn more.

Registration is NOW OPEN!

You could win a travel scholarship to the 2020 Annual Conference.  Learn more.

April 1 - 3, 2020
Salt Lake City, Utah, USA

Conference Chairs
<b>Jesús M Banales, PhD</b><br/>
Biodonostia Institute<br/>San Sebastián, Spain
Jesús M Banales, PhD
Biodonostia Institute
San Sebastián, Spain
<b>Rachna T Shroff, MD, MS</b><br/>
University of Arizona Cancer Center<br/>Tucson, Arizona, USA
Rachna T Shroff, MD, MS
University of Arizona Cancer Center
Tucson, Arizona, USA

2020 Cholangiocarcinoma Foundation Annual Conference

The 2020 Conference will build upon the foundation laid at this year’s meeting as key opinion leaders both nationally and internationally, come together to collaborate and exchange knowledge. The program will seek to develop sustainable participation of the medical and research communities in the field of cholangiocarcinoma by:


Increasing the knowledge and understanding of attendees about key issues central to the prevention, diagnosis, treatment, and cure for cholangiocarcinoma

A New Perspective

Identifying gaps and gathering consensus on rapidly changing advances in basic, translational, and clinical research


Stimulating interdisciplinary cross-cooperation and sharing best practices by developing, strengthening, and supporting collaborations


Fostering dialogue and inspiring innovation across the world

Further, because patients living with cholangiocarcinoma have a direct stake in their own medical care and are in a unique position to provide input, CCF has expanded its Annual Conference to include programming that addresses questions and concerns that are important to patients and their families. Patients and caregivers—having experienced the disease firsthand—will be invited to learn about cholangiocarcinoma, share their personal experiences, and contribute to future efforts to further cholangiocarcinoma research.

Who Should Attend?

Who Should Attend?

  • Researchers
  • Physicians
  • Oncologists
  • Radiologists
  • Surgeons
  • Gastroenterologists
  • Hepatologists
  • Nurses specializing in oncology, intensive care, and palliative care
  • Pharmaceutical Companies
  • Government Regulators
  • Policymakers
  • Patients, Caregivers and others invested in the field of cholangiocarcinoma

Incredible Numbers from our 2019 Conference


from 40 states and 12 countries representing healthcare, industry, patient advocacy organizations, patients, caregivers, academia and supporters.


including those by researchers, surgeons, patients, caregivers and industry specialists.


Medical Institutions

represented, including international key opinion leaders advancing cholangiocarcinoma research, treatment and care.


  • 200+ patients/caregivers
  • 29 poster presentations
  • 1,612 webcast attendees

with support from

  • 30 organizations: Agios, ASLAN Pharmaceuticals, Basiliea
    Pharmaceutica, Bayer, Beigene, Boston-Scientific, Bristol-Myers Squibb, Caris Life Sciences, Daiichi-Sankyo, DebiopharmGroup, EMD Serono, Foundation Medicine, Fujifilm, Incyte, Halozyme, Klus Pharma, Leap Therapeutics, Lexicon Pharmaceuticals, Merck, MundiPharma, NuCana, PCI Biotech, Pieris Pharmaceuticals, QED Therapeutics, RedHill Biopharma, Shepherd Therapeutics, Sirtex, Taiho Oncology, TriSalus Life Sciences, Zymeworks.

Sequoia Level

Oak Level

Cedar Level

Maple Level

Funding for this conference was made possible (in part) by 1R13CA246934 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.